Back to Search
KATAYOUN REZVANI, M.D.,PHD
M.D.,PHD
Internal Medicine Physician
NPI: 1760749204IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
43866(TX)
CMS Specialties
PrimaryHEMATOPOIETIC CELL TRANSPLANTATION AND CELLULAR THERAPY
Additional
Education
OTHER
Class of 1993
Research & Publications (20)
UBXD4, a UBX-containing protein, regulates the cell surface number and stability of alpha3-containing nicotinic acetylcholine receptors.
PMID 19474315·J Neurosci·2009
7-preclinical
Nicotine regulates multiple synaptic proteins by inhibiting proteasomal activity.
PMID 17898222·J Neurosci·2007
7-preclinical
Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
PMID 18988867·Blood·2009
8-other
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
PMID 19344397·Br J Haematol·2009
8-other
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.
PMID 19377081·Haematologica·2009
8-other
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
PMID 17875804·Blood·2008
3-trial
A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.
PMID 17878399·Blood·2008
8-other
The role of the immune system in myelodysplasia: implications for therapy.
PMID 18179968·Semin Hematol·2008
6-review
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
PMID 18716134·Blood·2008
8-other
Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
PMID 18548092·Leukemia·2008
8-other
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.
PMID 18790448·Best Pract Res Clin Haematol·2008
6-review
Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
PMID 17505014·Blood·2007
8-other
Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.
PMID 17673900·Leukemia·2007
8-other
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.
PMID 17412886·Blood·2007
8-other
Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.
PMID 17437417·Clin Exp Immunol·2007
6-review
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia.
PMID 17463169·Blood·2007
3-trial
Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity.
PMID 17464756·Cytotherapy·2007
5-case
Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.
PMID 17478639·Blood·2007
3-trial
Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.
PMID 17889359·Biol Blood Marrow Transplant·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1760749204
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile